A Beast of Burden That Needs To Be Tamed?

Chemotherapy-induced neutropenia and febrile neutropenia in the U.S.

Pegfilgrastim biosimilars play a key role as affordable treatment options in preventing chemotherapy-induced neutropenia & febrile neutropenia in cancer patients.

Switching patients to biosimilars in inflammatory disease: exploring patient and physician perspectives

Biosimilars in IBD - making the transformative effect of anti-TNFs more widely available for patients

Informing and involving patients in their biosimilar treatment journey: Practical support for starting patients on, or switching them to, biosimilars

Levelling the playing field: How biosimilars can pave the way to equitable treatment for patients across Europe

Accelerating Biosimilars